Physiologically based pharmacokinetic modeling of long-acting extended-release naltrexone in pregnant women with opioid use disorder.  Shenkoya B, Gopalakrishnan M, Eke AC.  CPT Pharmacometrics Syst Pharmacol. 2024 Nov;13(11):1939-1952...

Maternal exposure to buprenorphine, but not methadone, during pregnancy reduces social play behavior across two generations of offspring.  Nyberg H, Bogen IL, Nygaard E, Achterberg M, Andersen JM.  Psychopharmacology (Berl). 2024 Dec 5...

Prenatal Opioid and Alcohol Exposures: Association with Altered Placental Serotonin Transporter Structure and/or Expression.  Darbinian N, Merabova N, Tatevosian G, Adele S, Darbinyan A, Morrison MF, DeVane CL, Ramamoorthy S, Goetzl L, Selze...

Buprenorphine Induces Human Fetal Membrane Sterile Inflammation.  Lynn T, Kelleher ME, Georges HM, McCauley EM, Logan RW, Yonkers KA, Abrahams VM.  bioRxiv [Preprint]. 2024 Nov 22:2024.11.22.624850. doi: 10.1101/2024.11.22.624850. PMID...

Systematic review of gabapentinoid use during pregnancy and its impact on pregnancy and childhood outcomes: A ConcePTION study.  Beau AB, Mo J, Moisset X, Bénévent J, Damase-Michel C.  Therapie. 2024 Oct 18:S0040-5957(24)00165-3. doi: ...

Reviewing the Impact of Maternal Opioid Use Disorder on Fetal Development and Long-Term Pediatric Health Outcomes.  Asad M, Bonner-Reid FT, Aldoohan F, Marrelli LM, Ghanie N, Attia Hussein Mahmoud H, Venkatraj Srividya S, Devadas Gandhi P, Z...